Damora Therapeutics (DMRA) Non Operating Investment Income (2021 - 2024)
Damora Therapeutics (DMRA) posted Non Operating Investment Income of $2000.0 for Q2 2024, down 93.75% on a QoQ basis from $32000.0 in Q1 2024, and down 92.0% year-over-year from $25000.0 in Q3 2023.
Damora Therapeutics (DMRA) Non Operating Investment Income (2021 - 2024) Analysis & Trends
Damora Therapeutics' Non Operating Investment Income history runs 4 years deep, the most recent figure standing at $2000.0 for Q2 2024.
- Quarterly Non Operating Investment Income fell 92.0% year-over-year to $2000.0 in Q2 2024, while the trailing twelve-month figure through Sep 2024 was $92000.0 (up 675.0% YoY) and the FY2023 annual result came in at $231000.0, up 189.19% from the prior year.
- Non Operating Investment Income was $2000.0 for Q2 2024 at Damora Therapeutics, down from $32000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $92000.0 in Q1 2023 and bottomed at -$205000.0 in Q1 2022.
- A 4-year average of -$25571.4 and a median of $12500.0 in 2021 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2022 — Non Operating Investment Income sank 404.35% — and 2023, when it surged 168.29%.
- Damora Therapeutics' Non Operating Investment Income stood at -$54000.0 in 2021, then sank by 250.0% to -$189000.0 in 2022, then surged by 130.69% to $58000.0 in 2023, then plunged by 96.55% to $2000.0 in 2024.
- Business Quant data shows DMRA's Non Operating Investment Income at $2000.0 in Q2 2024, $32000.0 in Q1 2024, and $58000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Damora Therapeutics | 1.01 Bn | 807.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Sep 30, 2023 | 56,000.00 |
| Sep 30, 2023 | 56,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Dec 31, 2022 | -189,000.00 |
| Dec 31, 2022 | -189,000.00 |
| Sep 30, 2022 | -82,000.00 |
| Sep 30, 2022 | -82,000.00 |
| Jun 30, 2022 | -70,000.00 |
| Jun 30, 2022 | -70,000.00 |
| Mar 31, 2022 | -205,000.00 |
| Mar 31, 2022 | -205,000.00 |